Public Health Emergency - Leading a Nation Prepared
The potential for an anthrax attack is still a very real and serious threat to national health security and BARDA is working in collaboration with our PHEMCE partners to continue the development of medical countermeasures to prevent and treat infection. Anthrax vaccines are a major component of the PHEMCE’s strategy to protect the American people from anthrax.
BARDA is supporting the following anthrax vaccines:
BARDA will work with its partners in the PHEMCE to continue to develop single-dose anthrax vaccines. In the future, U.S. government investments will focus on post-exposure vaccines that offer transformational improvements over a two-dose vaccine.
BARDA is not seeking additional anthrax vaccines under its existing
Broad Agency Announcement (BAA). However, BARDA is interested in expanding the availability of licensed anthrax vaccines to at-risk populations, including pediatric populations. For more information, see the
BARDA Broad Agency Announcement (AOI 1.3).
Home | Contact Us | Accessibility | Privacy Policies | Disclaimer | HHS Viewers & Players | HHS Plain Language
Assistant Secretary for Preparedness and Response (ASPR), 200 Independence Ave., SW, Washington, DC 20201
U.S. Department of Health and Human Services | USA.gov |
HealthCare.gov in Other Languages